Showing 1881-1890 of 5910 results for "".
- Lighthouse Guild and Bionic Sight Announce Partnership Designed to Expand Treatment Options for People Who Are Blindhttps://modernod.com/news/lighthouse-guild-and-bionic-sight-announce-partnership-designed-to-expand-treatment-options-for-people-who-are-blind/2481264/Lighthouse Guild and Bionic Sight announced that they are entering into a partnership designed to impoved the landscape of treatment for people who are blind. Bionic Sight’s technology focuses on restoring sight to patients with advanced stage blindness due to retinal de
- Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLighthttps://modernod.com/news/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight/2479143/Lumenis announced that the FDA has granted De Novo authorization for Lumenis’ newest intense pulsed light (IPL) device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). The Lumenis multicenter, double-blinded, randomized controlled FDA trial showed that
- Nicox Appoints New Chair of the Board and Directorhttps://modernod.com/news/nicox-appoints-new-chair-of-the-board-and-director/2482357/Nicox announced the appointment of the experienced healthcare executive Damian Marron as Chair of the Board of Directors. Marc Le Bozec, an experienced life sciences entrepreneur, was appointed as a new Director of Nicox. Jean-François Labbe is retir
- Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-screened-in-the-whistler-phase-3b-trial-of-ncx-470-in-glaucoma/2482018/Nicox announced that the first patient has been screened in the Whistler phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in IOP lowering. NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is the company's le
- American Academy of Optometry Launches Academy Online: An Online CE Platformhttps://modernod.com/news/american-academy-of-optometry-launches-academy-online-an-online-ce-platform/2480153/The American Academy of Optometry has announced the launch of a new online CE and resource platform, Academy Online. Users can find a collection of session recordings from past annual meetings as well as distance learning credits. This initiative is aimed at assisting optometrists and vision scie
- LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patientshttps://modernod.com/news/lumithera-provides-update-on-fda-review-of-valeda-treatment-for-dry-amd-patients/2482040/LumiThera announced an update on the regulatory status of the Valeda Light Delivery System. Following feedback from the FDA, a De Novo request to reclassify the Valeda Light Delivery System as a Class II device has been submitted for review. Under the De Novo request process, the V
- Valo Health Suspends Development of DR Drug Candidate After Phase 2 Study Resultshttps://modernod.com/news/valo-health-suspends-development-of-dr-drug-candidate-after-phase-2-study-results/2482594/Valo Health announced topline data from its phase 2 SPECTRA study of OPL-0401 in patients with diabetic retinopathy (DR). The study did not meet its primary or secondary endpoints based on the analysis in the prede&sh
- ViGeneron Rebrands as VeonGen Therapeutics; Announces FDA Rare Pediatric Disease Designation for Lead Gene Therapyhttps://modernod.com/news/vigeneron-rebrands-as-veongen-therapeutics-announces-fda-rare-pediatric-disease-designation-for-lead-gene-therapy/2482837/VeonGen Therapeutics announced its rebranding from ViGeneron to reflect its evolution into a clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs. VeonGen has advanc
- NIH-Led Science Team Defines Elements of Cerebral Vision Impairmenthttps://modernod.com/news/nih-led-science-team-defines-elements-of-brain-based-leading-cause-of-childhood-vision-loss/2482557/Cerebral (or cortical) vision impairment (CVI) is a leading cause of childhood vision impairment in the United States and other industrialized nations, affecting at least 3% of primary school children. As vision is closely tied to learn
- Lenz Therapeutics Completes Merger with Graphite Bio; Debuts on Nasdaqhttps://modernod.com/news/lenz-therapeutics-completes-merger-with-graphite-bio-to-debut-on-nasdaq/2482177/Lenz Therapeutics announced the completion of its previously announced merger with Graphite Bio. The new combined company will operate under the name Lenz Therapeutics and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. &ldquo